- Home
- SYTA vs SABS Comparison
SYTA vs SABS Comparison
Compare SYTA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYTA
- SABS
- Stock Information
- Founded
- SYTA N/A
- SABS 2014
- Country
- SYTA Canada
- SABS United States
- Employees
- SYTA N/A
- SABS N/A
- Industry
- SYTA Telecommunications Equipment
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- SYTA Telecommunications
- SABS Health Care
- Exchange
- SYTA Nasdaq
- SABS Nasdaq
- Market Cap
- SYTA 17.3M
- SABS 15.8M
- IPO Year
- SYTA 2020
- SABS N/A
- Fundamental
- Price
- SYTA $2.03
- SABS $1.78
- Analyst Decision
- SYTA
- SABS Strong Buy
- Analyst Count
- SYTA 0
- SABS 5
- Target Price
- SYTA N/A
- SABS $11.80
- AVG Volume (30 Days)
- SYTA 2.0M
- SABS 18.6K
- Earning Date
- SYTA 08-15-2025
- SABS 08-07-2025
- Dividend Yield
- SYTA N/A
- SABS N/A
- EPS Growth
- SYTA N/A
- SABS N/A
- EPS
- SYTA N/A
- SABS N/A
- Revenue
- SYTA $11,740,024.00
- SABS $377,835.00
- Revenue This Year
- SYTA $18.41
- SABS N/A
- Revenue Next Year
- SYTA N/A
- SABS N/A
- P/E Ratio
- SYTA N/A
- SABS N/A
- Revenue Growth
- SYTA 33.58
- SABS N/A
- 52 Week Low
- SYTA $0.93
- SABS $1.00
- 52 Week High
- SYTA $162.90
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- SYTA 43.33
- SABS 49.33
- Support Level
- SYTA $1.83
- SABS $1.60
- Resistance Level
- SYTA $2.30
- SABS $1.87
- Average True Range (ATR)
- SYTA 0.32
- SABS 0.11
- MACD
- SYTA -0.13
- SABS -0.01
- Stochastic Oscillator
- SYTA 12.12
- SABS 62.07
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.